




Instance: composition-en-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: CompositionUvEpi
Title: "Composition for integrilin Package Leaflet"
Description:  "Composition for integrilin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/99/109/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp444c9ba43fa8be9df56ba30d3dc13ea7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - integrilin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Integrilin is and what it is used for </li>
<li>What you need to know before you are given Integrilin </li>
<li>How to use Integrilin </li>
<li>Possible side effects </li>
<li>How to store Integrilin </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What integrilin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What integrilin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from 
forming.  </p>
<p>It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and recent 
chest pain with electrocardiographic abnormalities or biological changes. It is usually given with aspirin 
and unfractionated heparin. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You must not be given Integrilin: </p>
<p>if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 
6). </p>
<p>if you have recently had bleeding from your stomach, intestines, bladder or other organs, for 
example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
in the past 30 days. </p>
<p>if you have had a stroke within the past 30 days or any haemorrhagic stroke (also, be sure your 
doctor knows if you ever had a stroke). </p>
<p>if you have had a brain tumour or a condition that affects the blood vessels around the brain. </p>
<p>if you had a major operation or severe injury during the past 6 weeks. </p>
<p>if you have or have had bleeding problems. </p>
<p>if you have or have had difficulty with your blood clotting or a low blood platelet count. </p>
<p>if you have or have had severe hypertension (high blood pressure). </p>
<p>if you have or have had severe kidney or liver problems. </p>
<p>if you have been treated with another medicineof the same type as Integrilin. </p>
<p>Please tell your doctor if you have had any of these conditions. If you have any questions, ask your 
doctor or hospital pharmacist or nurse. </p>
<p>Take special care with Integrilin: </p>
<p>Integrilin is recommended for use only in adult, hospitalised patients in coronary care units. </p>
<p>Integrilin is not intended for use in children or adolescents less than 18 years of age. </p>
<p>Before and during your treatment with Integrilin, samples of your blood will be tested as a safety 
measure to limit the possibility of unexpected bleeding. 
During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected 
bleeding. </p>
<p>Other medicines and Integrilin 
To avoid the possibility of interactions with other medicines please tell your doctor or hospital 
pharmacist or nurse if you are taking or have recently taken or might take any other medicines, 
including medicines obtained without a prescription. Particularly: </p>
<p>blood thinners (oral anticoagulants) or </p>
<p>medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except 
those that you may be given as part of Integrilin treatment).  </p>
<p>Pregnancy and breast-feeding 
Integrilin is not usually recommended for use during pregnancy. Tell your doctor if you are pregnant, 
think you might be pregnant or are planning to have a baby. Your doctor will weigh up the benefit to 
you against the risk to your baby of using Integrilin while you are pregnant. </p>
<p>If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period. </p>
<p>Integrilin contains sodium </p>
<p>This medicine contains 161 mg sodium (main component of cooking/table salt) in each 100 ml 
vial. This is equivalent to 8.1% of the recommended maximum daily dietary intake of sodium 
for an adult. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin is given into the vein by direct injection followed by an infusion (drip solution). The dose 
given is based on your weight. The recommended dose is 180 microgram/kg administered as a bolus 
(rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 
72 hours. If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute. </p>
<p>If percutaneous coronary intervention (PCI) is performed during Integrilin therapy, the intravenous 
solution may be continued for up to 96 hours. </p>
<p>You must also be given doses of aspirin and heparin (if not contraindicated in your case). </p>
<p>If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or 
nurse. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Very common side effects 
These may affect more than 1 in 10 people </p>
<p>minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding 
with surgical procedures). </p>
<p>anaemia (decreased number of red blood cells).  </p>
<p>Common side effects 
These may affect up to 1 in 10 people </p>
<p>inflammation of a vein. </p>
<p>Uncommon side effects 
These may affect up to 1 in 100 people </p>
<p>reduction in the number of platelets (blood cells necessary for blood clotting). </p>
<p>reduced blood flow to the brain. </p>
<p>Very rare side effects 
These may affect up to 1 in 10,000 people </p>
<p>serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the 
lungs). </p>
<p>fatal bleeding. </p>
<p>severe reduction in the number of platelets (blood cells necessary for blood clotting). </p>
<p>skin rash (such as hives). </p>
<p>sudden, severe allergic reaction. </p>
<p>If you notice any signs of bleeding, notify your doctor or hospital pharmacist or nurse immediately. Very 
rarely, bleeding has become severe and even fatal. Safety measures to prevent this from happening 
include blood tests and careful checking by the healthcare professionals taking care of you.  </p>
<p>If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse 
immediately. </p>
<p>Other events that may occur in patients, who require this type of treatment, include those that are 
related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, 
shock or cardiac arrest. </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor, hospital pharmacist or nurse. This includes any possible 
side effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children  </p>
<p>Do not use this medicine after the expiry date (EXP) stated on the package and the vial. The expiry date 
refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). </p>
<p>Keep the vial in the outer package in order to protect from light. However, protection of Integrilin solution 
from light is not necessary during administration. </p>
<p>Before using, the vial contents should be inspected. 
Integrilin should not be used if it is noticed that particulate matter or discoloration is present.  </p>
<p>Any unused medicine after opening should be thrown away.   </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your hospital pharmacist how 
to throw away medicines you no longer use. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Integrilin contains </p>
<p>The active substance is eptifibatide. Each ml of solution for infusion contains 0.75 mg of 
eptifibatide. One vial of 100 ml of solution for infusion contains 75 mg of eptifibatide.  </p>
<p>The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections. </p>
<p>What Integrilin looks like and contents of the pack 
Integrilin solution for infusion: 100 ml vial, pack of one vial.  </p>
<p>The clear, colourless solution is contained in a 100 ml glass vial, which is closed with a butyl rubber 
stopper and sealed with a crimped aluminium seal. </p>
<p>Marketing Authorisation Holder and manufacturer </p>
<p>Marketing Authorisation Holder: </p>
<p>GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland </p>
<p>Manufacturer: </p>
<p>GlaxoSmithKline Manufacturing S.P.A., Strada Provinciale Asolana No. 90, San Polo di Torrile 
43056, Parma, Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
T l/Tel: + 32 (0) 10 85 52 Lietuva 
GlaxoSmithKline (Ireland) Limited<br />
Tel: +370 80000<br />
GlaxoSmithKline (Ireland) Limited 
 . +359 80018Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Belgique/Belgien 
T l/Tel: + 32 (0) 10 85 52  esk  republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 222 001 cz.info@gsk.com </p>
<p>Magyarorsz g 
GlaxoSmithKline (Ireland) Limited 
Tel.: +36 80088Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta 
GlaxoSmithKline (Ireland) Limited 
Tel: +356 80065Deutschland 
GlaxoSmithKline GmbH &amp; Co. KG 
Tel.: + 49 (0)89 36044 8produkt.info@gsk.com </p>
<p>Nederland 
GlaxoSmithKline BV 
Tel:  + 31 (0)33 2081Eesti 
GlaxoSmithKline (Ireland) Limited 
Tel: +372 8002Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 <br />
GlaxoSmithKline   A.E.B.E. 
 : + 30 210 68 82  sterreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com </p>
<p>Espa a 
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com </p>
<p>Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (0)22 576 9France 
Laboratoire GlaxoSmithKline 
T l.: + 33 (0)1 39 17 84 diam@gsk.com </p>
<p>Portugal 
GlaxoSmithKline   Produtos Farmac uticos, Lda 
Tel: + 351 21 412 95 FI.PT@gsk.com </p>
<p>Hrvatska 
GlaxoSmithKline (Ireland) Limited 
Tel: +385 800787Rom nia 
GlaxoSmithKline (Ireland) Limited 
Tel: +40 800672Ireland 
GlaxoSmithKline (Ireland) Limited 
Tel: + 353 (0)1 4955Slovenija 
GlaxoSmithKline (Ireland) Limited 
Tel: +386 80688 sland 
Vistor hf. 
S mi: + 354 535 7Slovensk  republika 
GlaxoSmithKline (Ireland) Limited 
Tel: +421 800500Italia 
GlaxoSmithKline S.p.A. 
Tel: + 39 (0)45 7741 Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 (0)10 30 30 <br />
GlaxoSmithKline (Ireland) Limited 
 : +357 80070Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com </p>
<p>Latvija 
GlaxoSmithKline (Ireland) Limited 
Tel: +371 80205United Kingdom (Northern Ireland) 
GlaxoSmithKline (Ireland) Limited 
Tel: + 44 (0)800 221customercontactuk@gsk.com 
This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: CompositionUvEpi
Title: "Composition for integrilin Package Leaflet"
Description:  "Composition for integrilin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/99/109/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp444c9ba43fa8be9df56ba30d3dc13ea7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - integrilin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at få Integrilin 
3. Sådan får du Integrilin 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What integrilin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What integrilin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin hæmmer sammenklumpning af blodplader. Det betyder, at det hjælper med at forebygge 
blodpropper. </p>
<p>Det bruges til voksne med tegn på svær koronarinsufficiens defineret som spontane og nylige 
brystsmerter med unormale ændringer i elektrokardiogrammet eller biologiske forandringer. Det gives 
normalt sammen med acetylsalicylsyre og ufraktioneret heparin. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Integrilin 
- hvis du er allergisk over for eptifibatid eller et af de øvrige indholdsstoffer i Integrilin (angivet i 
punkt 6) 
- hvis du for nyligt har haft blødning fra mave, tarm, blære eller andre organer, fx hvis du har 
observeret unormalt blod i afføring eller urin (undtagen fra menstruationsblødning) i de seneste 
30 dage 
- hvis du har haft et slagtilfælde inden for de sidste 30 dage eller nogen form for hjerneblødning 
(husk også at fortælle lægen, hvis du nogensinde har haft et slagtilfælde) 
- hvis du har haft en hjernetumor eller en tilstand, der påvirker blodkarrene omkring hjernen 
- hvis du har gennemgået en større operation eller er blevet alvorligt skadet inden for de sidste 
6 uger 
- hvis du har eller har haft blødningsproblemer 
- hvis du har eller har haft besvær med størkning af blod eller et lavt antal blodplader 
- hvis du har eller har haft svær hypertension (forhøjet blodtryk) 
- hvis du har eller har haft alvorlige nyre- eller leversygdomme 
- hvis du er blevet behandlet med anden medicin af samme type som Integrilin. </p>
<p>Fortæl det til lægen, hvis du lider af en af disse tilstande. Kontakt lægen eller sygeplejersken, hvis du har 
spørgsmål. </p>
<p>Advarsler og forsigtighedsregler 
- Integrilin anbefales kun til anvendelse hos voksne patienter indlagt på hjerteafdeling. 
- Integrilin er ikke beregnet til anvendelse hos børn eller unge under 18 år. 
- Før og under din behandling med Integrilin, vil du få taget blodprøver, der skal undersøges, for at 
begrænse risikoen for en uventet blødning. 
- Under brugen af Integrilin vil du blive omhyggeligt undersøgt for tegn på usædvanlig eller </p>
<p>uventet blødning. </p>
<p>Brug af anden medicin sammen med Integrilin 
For at undgå interaktioner med anden medicin, skal du altid fortælle det til lægen eller sygeplejersken, 
hvis du bruger anden medicin, for nylig har brugt anden medicin eller planlægger at bruge anden 
medicin. Dette gælder også medicin, som ikke er købt på recept. Især:</p>
<ul>
<li>blodfortyndende medicin (orale antikoagulantia) </li>
<li>medicin, der forebygger blodpropper, herunder warfarin, dipyridamol, ticlopidin, acetylsalicylsyre 
(undtagen den medicin, du kan få som en del af behandlingen med Integrilin). </li>
</ul>
<p>Graviditet og amning 
Integrilin anbefales normalt ikke til brug under graviditet. Fortæl det til lægen, hvis du er gravid, har 
mistanke om, at du er gravid, eller planlægger at blive gravid. Lægen vil opveje fordelene for dig ved at 
få Integrilin, mens du er gravid, op mod risikoen for dit ufødte barn. </p>
<p>Hvis du ammer, bør amningen afbrydes i behandlingsperioden. </p>
<p>Integrilin indeholder natrium 
Dette lægemiddel indeholder 161 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
100 ml hætteglas. Dette svarer til 8,1% af den anbefalede maximale daglige indtagelse 
af natrium for en voksen. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin gives i en blodåre ved direkte injektion efterfulgt af infusion (drop). Den givne dosis er baseret 
på din vægt. Den sædvanlige dosis er 180 mikrogram/kg indgivet som bolus (hurtig intravenøs 
injektion), efterfulgt af infusion (drop) på 2 mikrogram/kg/minut i op til 72 timer. Hvis du har nedsat 
nyrefunktion, kan dosis blive nedsat til 1 mikrogram/kg/minut. </p>
<p>Hvis perkutan koronarintervention (PCI) foretages under behandlingen med Integrilin, kan behandlingen 
fortsættes i indtil 96 timer. </p>
<p>Du skal også have acetylsalicylsyre og heparin (medmindre du ikke kan tåle disse). </p>
<p>Spørg lægen eller sygeplejersken, hvis du har spørgsmål til brugen af dette produkt. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelige bivirkninger<br />
Dette kan forekomme hos flere end 1 ud af 10 patienter 
- større eller mindre blødning (fx blod i urin eller afføring, i opkast eller i forbindelse med 
operation) 
- blodmangel (nedsat antal røde blodlegemer). </p>
<p>Almindelige bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 10 patienter 
- betændelse i en blodåre. </p>
<p>Ikke almindelige bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 100 patienter 
- nedsat antal blodplader (celler, der får blodet til at størkne) 
- nedsat blodtilførsel til hjernen. </p>
<p>Meget sjældne bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 10.000 patienter 
- alvorlig blødning (fx blødende mavesår, hjerneblødning, eller blødning i lungerne) 
- blødning med dødelig udgang 
- alvorligt nedsat antal blodplader (celler, der får blodet til at størkne) 
- kløende udslæt, såsom nældefeber 
- pludselig, alvorlig allergisk reaktion. </p>
<p>Hvis du bemærker nogen tegn på blødning, så kontakt straks lægen eller sygeplejersken. Blødning har i 
sjældne tilfælde vist sig at være meget alvorlig eller endog livstruende. De forholdsregler, der tages for at 
undgå blødning, inkluderer blodprøver og omhyggelige lægeundersøgelser.  </p>
<p>Hvis du får en alvorlig allergisk reaktion eller kløende udslæt, så kontakt straks lægen eller 
sygeplejersken. </p>
<p>Øvrige bivirkninger, der kan forekomme hos patienter, der har behov for denne slags behandling, er 
forbundet med den sygdom, du behandles for, såsom hurtigt eller uregelmæssigt hjerteslag, lavt blodtryk, 
shock eller hjertestop. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og på hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). </p>
<p>Opbevares i den originale yderpakning for at beskytte mod lys. Det er ikke nødvendigt at beskytte 
Integrilin mod lys under behandlingen. </p>
<p>Inspicer indholdet af hætteglasset før brug. 
Brug ikke Integrilin, hvis der er bundfald eller misfarvning. </p>
<p>Bortskaf al ikke anvendt lægemiddel efter åbning. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin indeholder:</p>
<ul>
<li>Aktivt stof: eptifibatid. Hver ml opløsning indeholder 0,75 mg eptifibatid. Et hætteglas med ml infusionsvæske indeholder 75 mg eptifibatid. </li>
<li>Øvrige indholdsstoffer: citronsyremonohydrat, natriumhydroxid og vand til injektionsvæske. </li>
</ul>
<p>Udseende og pakningstørrelser 
Integrilin infusionsvæske, opløsning: 100 ml hætteglas, pakning med 1 hætteglas.  </p>
<p>Klar, farveløs opløsning i 100 ml hætteglas, lukket med butylgummiprop og forseglet med krympesegl 
i aluminium. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: </p>
<p>GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irland </p>
<p>Fremstiller: </p>
<p>GlaxoSmithKline Manufacturing S.P.A., Strada Provinciale Asolana No. 90, San Polo di Torrile 
43056, Parma, Italien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 (0) 10 85 52<br />
Lietuva 
GlaxoSmithKline (Ireland) Limited<br />
Tel: +370 80000 
България 
GlaxoSmithKline (Ireland) Limited 
Тел. +359 80018 
Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Belgique/Belgien 
Tél/Tel: + 32 (0) 10 85 52<br />
Česká republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 222 001 cz.info@gsk.com </p>
<p>Magyarország 
GlaxoSmithKline (Ireland) Limited 
Tel.: +36 80088 
Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta 
GlaxoSmithKline (Ireland) Limited 
Tel: +356 80065 
Deutschland 
GlaxoSmithKline GmbH &amp; Co. KG 
Tel.: + 49 (0)89 36044 8produkt.info@gsk.com </p>
<p>Nederland 
GlaxoSmithKline BV 
Tel:  + 31 (0)33 2081 
Eesti 
GlaxoSmithKline (Ireland) Limited 
Tel: +372 8002 
Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20<br />
Ελλάδα 
GlaxoSmithKline Μονοπρόσωπη A.E.B.E. 
Τηλ: + 30 210 68 82<br />
Österreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com </p>
<p>España 
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com </p>
<p>Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (0)22 576 9 
France 
Laboratoire GlaxoSmithKline 
Tél.: + 33 (0)1 39 17 84 diam@gsk.com </p>
<p>Portugal 
GlaxoSmithKline - Produtos Farmacêuticos, Lda 
Tel: + 351 21 412 95 FI.PT@gsk.com </p>
<p>Hrvatska 
GlaxoSmithKline (Ireland) Limited 
Tel: +385 800787 
România 
GlaxoSmithKline (Ireland) Limited 
Tel: +40 800672 
Ireland 
GlaxoSmithKline (Ireland) Limited 
Tel: + 353 (0)1 4955 
Slovenija 
GlaxoSmithKline (Ireland) Limited 
Tel: +386 80688 
Ísland 
Vistor hf. 
Sími: + 354 535 7 
Slovenská republika 
GlaxoSmithKline (Ireland) Limited 
Tel: +421 800500 
Italia 
GlaxoSmithKline S.p.A. 
Tel: + 39 (0)45 7741<br />
Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 (0)10 30 30<br />
Κύπρος 
GlaxoSmithKline (Ireland) Limited 
Τηλ: +357 80070 
Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com </p>
<p>Latvija 
GlaxoSmithKline (Ireland) Limited 
Tel: +371 80205 
United Kingdom (Northern Ireland) 
GlaxoSmithKline (Ireland) Limited 
Tel: + 44 (0)800 221customercontactuk@gsk.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. 
Indlægsseddel: Information til patienten </p>
<p>Integrilin 2 mg/ml injektionsvæske, opløsning 
eptifibatid </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at få dette lægemiddel, da den indeholder 
vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller sygeplejersken, hvis der er mere, du vil vide. 
- Kontakt lægen eller sygeplejersken, hvis du får bivirkninger, herunder bivirkninger, som ikke 
er nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlægsseddel.dk. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for integrilin Package Leaflet for language en"
Description: "ePI document Bundle for integrilin Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-444c9ba43fa8be9df56ba30d3dc13ea7"
* entry[0].resource = composition-en-444c9ba43fa8be9df56ba30d3dc13ea7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp444c9ba43fa8be9df56ba30d3dc13ea7"
* entry[=].resource = mp444c9ba43fa8be9df56ba30d3dc13ea7
                            
                    
Instance: bundlepackageleaflet-da-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for integrilin Package Leaflet for language da"
Description: "ePI document Bundle for integrilin Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-444c9ba43fa8be9df56ba30d3dc13ea7"
* entry[0].resource = composition-da-444c9ba43fa8be9df56ba30d3dc13ea7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp444c9ba43fa8be9df56ba30d3dc13ea7"
* entry[=].resource = mp444c9ba43fa8be9df56ba30d3dc13ea7
                            
                    



Instance: mp444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product INTEGRILIN 0.75 mg/ml solution for infusion"
Description: "INTEGRILIN 0.75 mg/ml solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/99/109/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "INTEGRILIN 0.75 mg/ml solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 444c9ba43fa8be9df56ba30d3dc13ea7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "integrilin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with integrilin"

* subject = Reference(mp444c9ba43fa8be9df56ba30d3dc13ea7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#integrilin "integrilin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-444c9ba43fa8be9df56ba30d3dc13ea7) // integrilin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-444c9ba43fa8be9df56ba30d3dc13ea7) // integrilin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: List

* insert 444c9ba43fa8be9df56ba30d3dc13ea7ListRuleset
    